Grifols Is Good Buy, Shares Have 20% Upside, Says Oddo & Cie
Alert: HALISTER1
Source: BFW (Bloomberg First Word)
Tickers
GRF SM (Grifols SA)
People
Pierre Corby (Oddo & Cie)
Sebastien Malafosse (Oddo & Cie SCA)
Topics
Holding Increases
To de-activate this alert, click here
To modify this alert, click here
UUID: 7947283
(Bloomberg) -- Grifols laboratories are a unique opportunity in healthcare as world’s only pure player of significant size in plasma derivatives, Oddo & Cie analysts Sebastien Malafosse and Pierre Corby write in note.
- Plasma derivatives -- proteins extracted from blood donors’ plasma for therapeutic use -- is a dynamic market relatively sheltered from price pressure
- Treatments in plasma derivatives market combined represented global revenues of EU18b in 2016
- Grifols is in good position, with 18% market share, to outperform sector over the next few years with EPS CAGR of 15% vs 12.7% for specialty pharma players
- Co. should post annual sales growth of 5.1% over next 5 years
- Initiates share coverage with a buy rating
Alert: HALISTER1
Source: BFW (Bloomberg First Word)
Tickers
GRF SM (Grifols SA)
People
Pierre Corby (Oddo & Cie)
Sebastien Malafosse (Oddo & Cie SCA)
Topics
Holding Increases
To de-activate this alert, click here
To modify this alert, click here
UUID: 7947283